212 related articles for article (PubMed ID: 22542812)
1. Clinical decision support with automated text processing for cervical cancer screening.
Wagholikar KB; MacLaughlin KL; Henry MR; Greenes RA; Hankey RA; Liu H; Chaudhry R
J Am Med Inform Assoc; 2012; 19(5):833-9. PubMed ID: 22542812
[TBL] [Abstract][Full Text] [Related]
2. Formative evaluation of the accuracy of a clinical decision support system for cervical cancer screening.
Wagholikar KB; MacLaughlin KL; Kastner TM; Casey PM; Henry M; Greenes RA; Liu H; Chaudhry R
J Am Med Inform Assoc; 2013; 20(4):749-57. PubMed ID: 23564631
[TBL] [Abstract][Full Text] [Related]
3. Impact of Patient Reminders on Papanicolaou Test Completion for High-Risk Patients Identified by a Clinical Decision Support System.
MacLaughlin KL; Kessler ME; Komandur Elayavilli R; Hickey BC; Scheitel MR; Wagholikar KB; Liu H; Kremers WK; Chaudhry R
J Womens Health (Larchmt); 2018 May; 27(5):569-574. PubMed ID: 29297754
[TBL] [Abstract][Full Text] [Related]
4. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
Della Palma P; Moresco L; Giorgi Rossi P
Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
[TBL] [Abstract][Full Text] [Related]
5. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
6. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
[TBL] [Abstract][Full Text] [Related]
7. Improving the Accuracy of a Clinical Decision Support System for Cervical Cancer Screening and Surveillance.
Ravikumar KE; MacLaughlin KL; Scheitel MR; Kessler M; Wagholikar KB; Liu H; Chaudhry R
Appl Clin Inform; 2018 Jan; 9(1):62-71. PubMed ID: 29365341
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
[TBL] [Abstract][Full Text] [Related]
10. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
11. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
12. Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination.
Malo TL; Perkins RB; Lee JH; Vadaparampil ST
Sex Transm Dis; 2016 Jul; 43(7):438-44. PubMed ID: 27322046
[TBL] [Abstract][Full Text] [Related]
13. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.
Lytwyn A; Sellors JW; Mahony JB; Daya D; Chapman W; Ellis N; Roth P; Lorincz AT; Gafni A
CMAJ; 2000 Sep; 163(6):701-7. PubMed ID: 11022584
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
[No Abstract] [Full Text] [Related]
16. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
17. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
[TBL] [Abstract][Full Text] [Related]
18. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
[TBL] [Abstract][Full Text] [Related]
20. [Attendance rate in the Polish Cervical Cancer Screening Program in the years 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Rokita W; Molińska-Glura M; Januszek-Michalecka L; Seroczyński P; Uchlik J; Nowak-Markwitz E
Ginekol Pol; 2010 Sep; 81(9):655-63. PubMed ID: 20973201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]